Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel for patients with R/R indolent non-Hodgk...

Celý popis

Podrobná bibliografie

Vydáno v:	Blood Ročník 143; číslo 6; s. 496
Hlavní autoři:	Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A Scott, Miao, Harry, Beygi, Sara, Jacobson, Caron A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 08.02.2024
Témata:	Antigens, CD19 - therapeutic use Biological Products - therapeutic use Follow-Up Studies Humans Immunotherapy, Adoptive - adverse effects Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, Follicular - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Neoplasm Recurrence, Local - drug therapy
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!